VYNE Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Dave Domzalski
Chief executive officer
US$2.7m
Total compensation
CEO salary percentage | 23.5% |
CEO tenure | 4yrs |
CEO ownership | 0.2% |
Management average tenure | 4yrs |
Board average tenure | 3yrs |
Recent management updates
Recent updates
We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate
May 04VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M
Aug 12Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky
Jul 02VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely
Mar 19VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan
Jan 13VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely
Dec 03Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13VYNE Therapeutics: Terrible Depreciation Of Shareholder Value
Jun 30Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt
Jun 07Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts
Feb 17Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)
Feb 10VYNE Therapeutics closes capital raise of $50M
Jan 29What Is The Ownership Structure Like For VYNE Therapeutics Inc. (NASDAQ:VYNE)?
Jan 06VYNE Therapeutics reports successful FDA meeting for FCD105 in acne
Dec 17Have Insiders Been Buying VYNE Therapeutics Inc. (NASDAQ:VYNE) Shares?
Dec 08CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$3m | US$638k | -US$28m |
Sep 30 2023 | n/a | n/a | -US$29m |
Jun 30 2023 | n/a | n/a | -US$33m |
Mar 31 2023 | n/a | n/a | -US$31m |
Dec 31 2022 | US$1m | US$638k | -US$34m |
Sep 30 2022 | n/a | n/a | -US$35m |
Jun 30 2022 | n/a | n/a | -US$40m |
Mar 31 2022 | n/a | n/a | -US$42m |
Dec 31 2021 | US$5m | US$638k | -US$44m |
Sep 30 2021 | n/a | n/a | -US$59m |
Jun 30 2021 | n/a | n/a | -US$69m |
Mar 31 2021 | n/a | n/a | -US$226m |
Dec 31 2020 | US$3m | US$501k | -US$256m |
Sep 30 2020 | n/a | n/a | -US$270m |
Jun 30 2020 | n/a | n/a | -US$269m |
Mar 31 2020 | n/a | n/a | -US$120m |
Dec 31 2019 | n/a | n/a | -US$95m |
Sep 30 2019 | n/a | n/a | -US$71m |
Jun 30 2019 | n/a | n/a | -US$64m |
Mar 31 2019 | n/a | n/a | -US$63m |
Dec 31 2018 | US$1m | US$440k | -US$74m |
Sep 30 2018 | n/a | n/a | -US$77m |
Jun 30 2018 | n/a | n/a | -US$80m |
Mar 31 2018 | n/a | n/a | -US$77m |
Dec 31 2017 | US$3m | US$417k | -US$66m |
Compensation vs Market: Dave's total compensation ($USD2.72M) is above average for companies of similar size in the US market ($USD658.28K).
Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.
CEO
Dave Domzalski (56 yo)
4yrs
Tenure
US$2,716,350
Compensation
Mr. David T. Domzalski, also known as Dave, has been President, Chief Executive Officer and Director at VYNE Therapeutics Inc. (formerly known as Menlo Therapeutics Inc.). since March 9, 2020. Mr. Domzalsk...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 4yrs | US$2.72m | 0.24% $ 101.0k | |
Chief Scientific Officer | 4yrs | US$1.16m | 0.051% $ 21.2k | |
General Counsel | 4yrs | US$1.13m | 0.15% $ 62.9k | |
CFO & Treasurer | 2.8yrs | no data | 0.94% $ 390.2k | |
Consultant | 5.3yrs | US$115.20k | no data |
4.0yrs
Average Tenure
50yo
Average Age
Experienced Management: VYNE's management team is considered experienced (4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 4yrs | US$2.72m | 0.24% $ 101.0k | |
Lead Independent Director | 3.5yrs | US$123.60k | 0.26% $ 108.0k | |
Director | 8.5yrs | US$83.60k | 0.053% $ 22.1k | |
Independent Non-Employee Director | 4yrs | US$101.10k | 0.013% $ 5.6k | |
Independent Director | 5yrs | US$69.10k | 0% $ 0 | |
Independent Director | less than a year | no data | no data | |
Independent Non Employee Director | 4yrs | US$116.10k | 0.0074% $ 3.1k | |
Member of Scientific Advisory Board | 2.4yrs | no data | no data | |
Member of Scientific Advisory Board | 2.4yrs | no data | no data | |
Member of Scientific Advisory Board | 2.4yrs | no data | no data | |
Member of Scientific Advisory Board | 2.4yrs | no data | no data | |
Member of Scientific Advisory Board | 2.4yrs | no data | no data |
3.0yrs
Average Tenure
61yo
Average Age
Experienced Board: VYNE's board of directors are not considered experienced ( 3 years average tenure), which suggests a new board.